Methoxphenidine

Methoxphenidine

Systematic (IUPAC) name
(±)-1-[1-(2-methoxyphenyl)-2-phenylethyl]piperidine
Clinical data
Legal status	Illegal in China and Sweden
Routes of administration	Oral, Rectal
Identifiers
CAS Number	127529-46-8 Y
PubChem	CID: 67833251
Chemical data
Formula	C20H25NO
Molecular mass	295.4186 g/mol
SMILES COC1=C(C=CC=C1)C(CC2=CC=CC=C2)N3CCCCC3
InChI InChI=1S/C20H25NO/c1-22-20-13-7-6-12-18(20)19(21-14-8-3-9-15-21)16-17-10-4-2-5-11-17/h2,4-7,10-13,19H,3,8-9,14-16H2,1H3 Key:QXXCUXIRBHSITD-UHFFFAOYSA-N

Methoxphenidine (methoxydiphenidine, 2-MeO-Diphenidine, MXP) is a dissociative of the diarylethylamine class that has been sold online as a designer drug. Methoxphenidine was first reported in a 1989 patent where it was tested as a treatment for neurotoxic injury. Shortly after the 2013 UK ban on arylcyclohexylamines methoxphenidine and the related compound diphenidine became available on the gray market, where it has been encountered as a powder and in tablet form. Though diphenidine possesses higher affinity for the NMDA receptor, anecdotal reports suggest methoxphenidine has greater oral potency. Of the three isomeric anisyl-substituents methoxphenidine has affinity for the NMDA receptor that is higher than 4-MeO-Diphenidine but lower than 3-MeO-Diphenidine, a structure–activity relationship shared by the anisylcyclohexylamines.

Side effects

Acute methoxphenidine intoxication has been reported to produce confusion, hypertension, and tachycardia that was responsive to treatment with intravenous lorazepam, methoxphenidine has also been associated with three published fatalities and one case of impaired driving.

Legal Status

As of October 2015 MXP is a controlled substance in China.

MXP is also banned in Sweden.

See also

• AD-1211
• Diphenidine
• Ephenidine
• Fluorolintane
• Lanicemine
• Lefetamine
• MT-45
• NMDA receptor antagonist
• Phencyclidine